China-based oncology medicine developer Elpiscience Biopharmaceuticals has raised $35m in a series A-plus round that included pharmaceutical company Eli Lilly, China Money Network reported today.
Hillhouse Capital led the round, which also included asset management firm CDH Investments. Eli Lilly participated through its regional corporate venturing division, Lilly Asia Ventures.
Elpiscience developes medicines and cancer immunotherapies that mobilise the immune system to combat and kill the disease. Its products target four major categories – adaptive immunity, innate immunity, tumour microenvironment and tumour-specific antigen.
Lilly Asia Ventures previously led a series A round, with China Money Network noting that Elpiscience had raised a total of $55m to date. However, further details could not be ascertained.